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Abstract: Patients admitted to hospital after being diagnosed with ﬁ  rst-episode schizophrenia 
were comprehensively assessed prior to acute treatment (on admission), at the end of the acute 
treatment (at discharge), and at follow-up after 1 year. The psychopathology was evaluated 
using the Positive and Negative Syndrome Scale (PANSS). 93 patients were reassessed after 
1 year. 73/93 (78%) of the patients fulﬁ  lled the criteria for remission. No statistically signiﬁ  cant 
differences in the total PANSS or subscales scores were found between remitters and non-
remitters before or after the ﬁ  rst episode treatment. However, non-remitters had a signiﬁ  cantly 
higher total PANSS score after 1 year than remitters. There was no signiﬁ  cant difference in mean 
psychopathology on admission or at discharge, with the exception of items conceptual disorga-
nization, difﬁ  culty in abstract thinking, and lack of judgment and insight between remitters and 
non-remitters. However, signiﬁ  cantly higher mean values were found for all items after 1 year 
in non-remitters than remitters. On admission the occurrence of positive, negative and general 
symptoms was balanced; at discharge and after 1 year negative and general symptoms were the 
most frequently observed. At the 1-year follow-up the impairment of insight and judgment is 
one of the most frequent symptoms in both remitters (10%) and non-remitters (70%).
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Introduction
The diagnosis of schizophrenia is associated with substantial variability between 
patients with regard to symptoms, treatment response, course, and etiologic risk factor 
dimension (Arango et al 2004; Keshavan et al 2004). The early course of schizophrenia, 
in particular, is highly variable across patients and is not generally well character-
ized in the literature. It seems that the occurrence of individual symptoms and their 
dynamics are very important for the outcome, but such a detailed analysis has not, to 
our knowledge, been published. Some symptoms may be state dependent and vary 
also in patients with a different outcome. 
Our department has been specializing, on a long-term basis, in the problems of ﬁ  rst 
episodes and investigation of individual biological markers of this disease. Since 1996 
we have recorded in our databases more than 160 male patients who have been observed 
longitudinally from the ﬁ  rst index hospitalization. The patients are reassessed at 1-, 3-, 
5-, and 10-year follow-ups. We evaluate psychopathology, neuropsychological proﬁ  le, 
neuroendocrinology parameters, neurological soft signs, and data from structural and 
functional neuroimaging methods (Češková et al 2003, 2005; Přikryl et al 2006). The 
aim of this study was a comparison of temporal changes in psychopathology between 
remitters and non-remitters at the 1-year follow-up. 
Methods
The study was designed as an open, naturalistic, follow-up study. Included in the 
study were males hospitalized for the first time with the diagnosis first-episode Neuropsychiatric Disease and Treatment 2007:3(1) 154
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schizophrenia (according to ICD-10 diagnostic criteria for 
research), who provided written informed consent, and 
were reassessed at the 1-year follow-up. ICD-10 diagnoses 
were made on the basis of a comprehensive assessment of 
symptoms and history, and all other available information 
about the patients. The diagnosis was conﬁ  rmed by consensus 
of two psychiatrists during separate interviews.
Clinical assessment 
The psychopathology was evaluated using the Positive and 
Negative Syndrome Scale (PANSS, Kay et al 1987) before 
the acute treatment (on admission), at the end of the acute 
treatment (at discharge), and at follow-up after 1 year. The 
patients were divided into remitters and non-remitters when 
they were reassessed after one year. For remission achieve-
ment a score of 3 (mild) or less was required in all eight of 
the following PANSS items: P1 delusions, P2 conceptual 
disorganization, P3 hallucinatory behaviour, G5 manner-
isms and posturing, G9 unusual thought content, N1 blunted 
affect, N4 passive/apathetic social withdrawal, N6 lack of 
spontaneity, and ﬂ  ow of conversation for a minimum of 6 
months (Kane et al 2003; Andreasen et al 2005).
Treatment
Most patients were drug-naïve on admission. After a baseline 
assessment all patients were treated openly by monotherapy 
with an antipsychotic chosen by the patient’s treating clini-
cian and individually dosed. Risperidone was the drug of 
ﬁ  rst choice; other options were selected according to clinical 
judgment and drug availability. The only concomitant treat-
ments allowed were benzodiazepines for tension, anxiety, 
and insomnia, and biperidene for extrapyramidal symptoms. 
After discharge from the index hospitalization the patients 
were treated as outpatients. 
Statistical analysis
The statistical analysis was based on descriptive statistics and 
nonparametric methods (the Mann-Whitney U test, Wilcoxon 
matched paired test, chi square test) and performed using 
STATISTICA software, version 6. 
Results
Sample characteristics
93 patients (mean age 23 years, mean duration of illness 
0.77 years) were reassessed after 1 year. 73/93 (78%) of the 
patients fulﬁ  lled the criteria for remission. The average daily 
dose of antipsychotics during the index hospitalization and at 
the 1-year follow-up was 228 mg and 127 mg, respectively. 
17/93 (18.3%) of the patients had discontinued their medica-
tion, the rate of discontinuation was higher in non-remitters 
7/20 (35%) than in remitters 10/73 (13.7%) (NS). 
Psychopathology—the total PANSS score 
No statistically signiﬁ  cant differences in the total PANSS 
or subscales scores were found between remitters and non-
remitters before or after the ﬁ  rst episode treatment. However, 
Figure 1 Psychopathology: comparison between remitters and non-remitters.
Note: *signiﬁ  cant difference between remitters and non-remitters (p < 0.001).
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non-remitters had a signiﬁ  cantly higher total PANSS score 
after 1 year than remitters (p < 0.001) (Figure 1, Table 1).
The relative decrease of psychopathology was evaluated 
using delta PANSS 1 (100 × ( PANSS on admission—PANSS 
at discharge)/PANSS at discharge). The relative decrease of 
total psychopathology during the index hospitalization was 
similar in both remitters ( 38.6%) and non-remitters ( 36.8%). 
Similar values for delta positive , negative and general 
PANSS 1 were found for both remitters (50.6%, 27.8%, 
35.4%) and non-remitters (52.4%, 25.7%, 32.4%).
After 1 year, there was further relative decrease found in 
remitters (20.7% ) and a signiﬁ  cant increase in non-remitters 
(–71.0%, p < 0.001 in relation to the end of acute treatment) 
using delta PANSS 2 (100x (PANSS at discharge—PANSS after 
1 year/PANSS after 1 year). Again, similar values were found for 
delta positive, negative, and general PANSS 2 in both remitters 
(17.6%, 20.3%, 19.4%) and non-remitters (–97.1%, –86.4%, 
–61.2%, p < 0.001 in relation to the end of acute treatment) .
Psychopathology—individual PANSS 
items (mean values)
When the remitters and non-remitters were compared, there 
was no signiﬁ  cant difference in mean psychopathology 
on admission or at discharge, with the exception of items 
conceptual disorganization, difﬁ  culty in abstract thinking 
and lack of judgment and insight. The mean values of these 
three items were actually lower in non-remitters at discharge. 
However, signiﬁ  cantly higher mean values were found for 
all items after 1 year in non-remitters than remitters (see 
Table 2)
Table 1 Comparison of individual PANSS items in remitters and non-remitters—mean values (SD)
Measure  Admission  Admission  Discharge  Discharge  After 1 year  After 1 year 
  Remitters  Non-remit.    Remitters Non-remit  Remitters Non-remit
P1 delusions  4.7 (1.6)  4.9 (1.9)  1.6 (0.9)  1.6 (1.0)  1.1 (0.5)  3.1 (2.1) *
P2 conceptual disorganization  4.0 (1.5)  3.2 (1.8)  1.8 (1.0)  1.3 (0.6) *  1.3 (0.6)  2.9 (1.8) *
P3 hallucinatory behavior  3.7(1.8)  3.6(2.0)  1.2 (0.6)  1.1 (0.7)  1.1 (0.4)  2.3 (1.9) *
P4 excitement  2.7 (1.6)  2.0 (1.1)  1.3 (0.7)  1.0 (0.2)  1.1 (0.5)  1.9 (1.3) *
P5 grandiosity  1.9 (1.4)  1.7 (1.3)  1.3 (0.7)  1.2 (0.7)  1.0 (0.3)  1.7 (1.1) *
P6 suspiciousness/persecutions  4.5 (1.1)  4.5 (1.3)  2.2 (0.9)  2.0 (0.9)  1.4 (0.6)  3.1 (1.7) *
P7 hostility  1.8 (1.3)  1.7 (1.5)  1.1 (0.3)  1.0 (0.3)  1.0 (0.2)  1.7 (1.1) *
Positive subscale PANSS   23.3 (6.1)  21.8 (5.3)   10.6 (3.3)  9.4 (3.3)  8.2 (2.0)  17.0(6.2) *
N1 blunted affect  3.2 (1.6)  3.2 (1.7)  2.6 (1.1)  2.5 (1.4)  1.9 (0.9)  3.6 (1.5) *
N2 emotional withdrawal  3.9 (1.5)  3.4 (1.4)  2.7 (1.0)  2.4 (1.1)  1.9 (0.9)  3.8 (1.6) *
N3 poor rapport  3.6 (1.7)  2.9 (1.5)  2.4 (1.1)  2.2 (0.9)  1.7 (0.8)  3.5 (1.5) *
N4 passive/apathetic social withdrawal  3.8 (1.7)  3.6 (1.4)  2.5 (1.0)  2.4 (1.2)  1.7 (0.8)  3.8 (1.8) *
N5 difﬁ  culty in abstract thinking  4.2 (1.9)  3.3 (2.0)  2.3 (1.2)  1.5 (0.8) *  1.7 (1.1)   3.2 (1.5) *
N6 lack of spontaneity   3.5 (1.7)  3.1 (1.9)  2.2 (1.1)  2.2 (0.9)  1.8 (0.9)  3.3 (1.6) *
N7 stereotyped thinking  4.0 (1.4)  3.7 (1.5)  2.5 (1.0)  2.2 (0.9)  1.8 (0.8)  3.5 (1.3) *
Negative subscale PANSS  26.2 (8.9)  23.4(8.7)  17.3 (5.9)  15.5 (6.3)  12.6 (5.0)  24.8 (8.5) *
G1 somatic concern  2.4 (1.8)  2.8 (1.9)  1.7 (0.9)  1.7 (1.0)  1.3 (0.7)  2.3 (1.5) *
G2 anxiety  2.8 (1.6)  2.7 (1.1)  1.4 (0.8)  1.4 (0.7)  1.2 (0.6)  1.9 (1.1) *
G3 guilt feelings  2.1 (1.4)  1.4 (1.0)  1.4 (0.9)  1.1 (0.5)  1.0 (0.3)  1.6 (1.0) *
G4 tension  2.7 (1.5)  2.3 (1.0)  1.5 (0.8)  1.3 (0.6)  1.3 (0.5)  2.5 (1.2) *
G5 mannerisms and posturing  2.4 (1.4)  2.0 (1.4)  1.7 (1.0)  1.5 (0.8)  1.2 (0.6)  2.9 (1.1) *
G6 depression  2.2 (1.4)  2.4 (1.3)  1.7 (1.0)  1.6 (0.9)  1.3 (0.8)  2.3 (1.5) *
G7 motor retardation  2.5 (1.5)  2.5 (1.3)  2.1 (1.0)  2.2 (1.0)  1.6 (0.8)  2.9 (1.3) *
G8 uncooperativeness  2.7 (1.8)  1.9 (1.6)  1.3 (0.5)  1.1 (0.5)  1.1 (0.4)  2.2 (1.6) *
G9 unusual thought content   3.6 (1.3)  3.4 (1.5)  1.7 (0.8)  1.7 (0.9)  1.3 (0.6)  2.8 (1.3) *
G 10 disorientation  1.9 (1.5)  1.5 (1.0)  1.0 (0.3)  1.0 (0.0)  1.0 (0.0)  1.1 (0.5) *
G11 poor attention  4.3 (1.1)  4.0 (1.0(  2.7 (0.8)  2.5 (1.0)  2.0 (0.9)  3.7 (1.0) *
G12 lack of judgment and insight  4.7 (1.4)  4.8 (1.4)  3.3 (1.1)  2.7 (1.0) *  2.1 (1.2)  4.2 (1.8) *
G13 disturbance of volition  3.9 (1.2)  3.1*(1.4)   2.6 (1.0)  2.3 (1.0)  1.8 (0.9)  3.3 (1.3) *
G14 poor impulse control  1.9 (1.3)  1.5 (1.3)  1.1 (0.5)  1.0 (0.0)  1.0 (0.3)  1.7 (1.2) *
G15 preoccupation  3.9 (1.4)  3.3 (1.2)  2.3 (1.0)  2.2 (1.0)  1.6 (0.8)  3.6 (1.3) *
G16 active social avoidance  3.9 (1.4)  3.2 (1.5)  2.3 (0.9)  2.3 (1.0)  1.70.9  3.3 (1.2) *
General subscale PANSS  48.1(11.9)  43.1 (9.6)  29.9(7.4)  27.5 (7.3)  22.9 (5.8)  42.8 (10.6) *
Total score PANSS  97.6 (22.3)  88.3 (19.9)  57.7 (14.4)  52.9 (14.9)  43.6 (11.0)  84.6 (21.6) *
Note: *signiﬁ  cant difference between remitters and non-remitters (p < 0.001).
Abbreviations: PANSS, Positive and Negative Syndrome Scale.Neuropsychiatric Disease and Treatment 2007:3(1) 156
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Psychopathology—occurrence of 
individual symptoms (relative values)
A categorical evaluation of individual symptoms was 
performed during the index hospitalization on admis-
sion and at discharge and after 1 year. A minimum score 
of 4 in the individual items was required for symptom 
presence.
On admission
Suspiciousness (86%), delusions and lack of judgment and 
insight (79 %), poor attention (74%), stereotyped thinking 
(67%), disturbance of volition (65%), conceptual disorga-
nization and active social avoidance (64%) were the most 
frequently observed symptoms on admission during the 
acute phase in remitters. Individual negative symptoms 
were present in about half of the patients. The occurrence 
of symptoms on admission was similar in non-remitters 
(Table 2, Figure 2). 
At discharge
At discharge, the most frequently found symptom in remitters 
was lack of judgment and insight (46.6%); in non-remitters, 
blunted affect (25%). Other most frequently observed symp-
toms were negative and non-speciﬁ  c symptoms in both the 
remitters and non-remitters (Table 2, Figure 3).
One-year follow-up
The lack of judgment and insight was the most frequent 
symptom in both remitters (10%) and non-remitters (70%) 
at the 1-year follow-up. In contrast to admission, the other 
most frequently observed symptoms were negative ones (with 
the exception of delusions) in non-remitters and non-speciﬁ  c 
general symptoms in remitters (Table 2, Figure 4).
Discussion
Our data on the occurrence of remission are in accordance 
with previously published studies. Remission of psychotic 
symptoms occurred in up to 80% at 1 year (Addington et al 
2003; Lieberman et al 2003). Malla et al (2000) also observed 
a complete remission rate of 70% in patients with ﬁ  rst episode 
schizophrenia at 1-year follow-up; however, remission was 
not deﬁ  ned according to Andreasen’s criteria.
In our sample 78% of the patients were remitters and 
we have found that 18% of the patients discontinued their 
Figure 2 The most frequent items on admission in remitters and non-remitters (%). 
Note: symptom presence—score minimally 4 for individual items.
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medication. However, there are some limitations in the 
interpretation of our results because 25% of the patients 
invited to participate could not be reached or declined to 
attend the reassessment after 1 year. Remission achievement 
and compliance of non-participants is unknown. Patients 
in the early course of schizophrenia frequently request a 
decrease or discontinuance of their antipsychotic medica-
tions, and many have poor adherence to treatment (Scottish 
schizophrenia research group 1987). Non-adherence is par-
ticularly prominent in ﬁ  rst episode patients (Novak-Grubic 
and Tavcar 1999). In Verdoux’s (2000) study the ﬁ  rst-ad-
mitted subjects with psychosis were assessed at 6-month 
intervals over a 2-year follow-up period. The proportion 
of subjects with poor medication adherence ranged from 
Table 2 Comparison of individual PANSS items between remitters and non-remitters—relative values
Measure  Admission  Admission  Discharge  Discharge  After 1 year  After 1 year 
  Remitters  Nonremit.    Remitters Nonremit Remitters Non-remit.
P1 delusions  79.4%  80.0%  2.7%  5.0%  0  50.0% 
P2 conceptual 
disorganization 63.0%  45.0%  5.4%  0  0  40.0%
P3 hallucinatory 
behavior 60.3%  65%  1.4%  5.0%  0  35.0%
P4  excitement  28.8%  10%  0 0%  0 15.0%
P5 grandiosity  19.1%  20%  1.4%  5%  0  10.0%
P6 suspiciousness/
persecutions 86.3%  85%  2.7%  5%  0  35.0%
P7  hostility  11.0%  10.0%  0 0 0 5.0%
N1 blunted affect  37.0%  45.0%  15.1%  25.0%  0  50.0%
N2 emotional 
withdrawal 64.4%  40.0%  16.4%  15.0%  0  50.0%
N3 poor rapport  42.5%  25.0%  10.9%  0  0  30%
N4 passive/apathetic 
social withdrawal  56.2%  45.0%  15.1%  15.0%  0  60.0%
N5 difﬁ  culty in 
abstract thinking  63.0%  35.0%  10.9%  0  5.5%  30.0%
N6 lack of 
spontaneity   50.7%  45.0%  6.8%  0  0  45.0%
N7 stereotyped 
thinking 67.1%  60.0%  12.3%  0  0  55.0%
G1 somatic concern  22.0%  35.0%  4.1%  5.0%  0  15.0%
G2  anxiety  31.5%  25.0%  0 0 0 10.0%
G3 guilt feelings  20.6%  10.0%  4.1%  0  0  5.0%
G4  tension  22.0%  10.0%  0 0 0 20.0%
G5 mannerisms and 
posturing 19.2%  15.0%  5.5%  0  0  35.0%
G6  depression  22%  20.%  5.5% 0  2.7% 25.0%
G7 motor retardation  31.5%  20.%  10.90  5.0%  1.4%  40.0%
G8  uncooperativeness  27.4%  15%  0 0 0 25.0%
G9 unusual thought 
content    50.7%  55.0%  0 0 0 35.0%
G 10 disorientation  19.2%  10.%  0  0  0  0
G11 poor attention  74.0%  60.0%  9.6%  15.0%  1.4%  55.0%
G12 lack of judgment 
and  insight  79.4%  90.0%  46.6% 20%  10.9% 70.0%
G13 disturbance of 
volition 65.7%  50.0%  15.1%  10.%  2.7%  45.0%
G14 poor impulse 
control  12.3%  10.0%  0 0 0 10.0%
G15  preoccupation  63.0%  45.0% 9.6% 5.0% 1.4% 50.0%
G16 active social 
avoidance 54.8%  40.0%  4.1%  5.0%  0  45.0%
Abbreviations: Positive and Negative Syndrome Scale.Neuropsychiatric Disease and Treatment 2007:3(1) 158
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Figure 3  The most frequent items at discharge in remitters and non-remitters (%). 
Note: symptom presence—score minimally 4 for individual items.
33% to 44% at each follow-up assessment. After successful 
antipsychotic treatment, many patients believe that they will 
no longer need medication. Given that the early course of 
the disorder is highly variable across patients and is gener-
ally not well characterized in literature, clinicians are hard 
put to insist on indeﬁ  nite antipsychotic treatment. The role 
of antipsychotics after the ﬁ  rst psychotic manifestation is 
not fully elucidated. However, medication discontinuation 
was strongly associated with the worse outcome deﬁ  ned in 
terms of the number of relapses in subjects suffering from 
ﬁ  rst-episode schizophrenia (Robinson et al 1999). There are 
also some hints about the neuroprotective role of atypical 
antipsychotics (Lieberman et al 2003). 
No statistically signiﬁ  cant differences in PANSS scores 
were found between remitters and non-remitters in the acute 
phase. Given the responsiveness of ﬁ  rst-episode patients to 
treatment, the further course from the ﬁ  rst psychotic episode 
is highly variable and some ﬁ  rst-episode patients become 
more treatment resistant over time. After one year we found 
that non-remitters had a signiﬁ  cantly higher total PANSS 
score than remitters. This means that the period after a ﬁ  rst 
psychotic manifestation is critical. 
Our previous ﬁ  ndings concerning acute treatment re-
sponsivity showed that in the ﬁ  rst psychotic manifestation 
the most frequently observed symptom was lack of judgment 
and insight, which persisted at discharge from the index hos-
pitalization. The negative symptoms improved less compared 
to the positive ones. On admission the responders had higher 
scores for most symptoms, both positive and negative, than 
nonresponders (Češková et al 2005). Similar results were 
found in this study. Both on admission and at discharge 
a trend towards a higher score for most symptoms was 
observed in remitters. The difference in the case of difﬁ  culty 
in abstract thinking and lack of judgment and insight has 
reached statistical signiﬁ  cance. Thus, there was no signiﬁ  cant 
difference between remitters and non-remitters in the acute 
phase. However, after 1 year non-remitters had signiﬁ  cantly 
higher mean scores for all PANSS items. 
On admission the occurrence of positive, negative, and 
general symptoms was balanced; at discharge and after 1 year 
negative and general symptoms were the most frequently 
observed; at the 1-year follow-up only general, non-speciﬁ  c 
symptoms were observed in remitters. In a methodologi-
cally sound study, Peralta (2000) concluded that negative 
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symptoms rated during a ﬁ  rst psychotic episode before and 
after starting antipsychotic treatment are mainly primary in 
character, and should be considered a direct manifestation of 
the basic dysfunctions of schizophrenia. Our results are also 
in agreement with the observation that negative symptoms 
decrease more slowly than positive ones and may persist in 
some of the patients. 
The impairment of insight and judgment was one of the 
most frequently observed items in both remitters and non-re-
mitters at all three time points. Insight in schizophrenia is im-
portant because of its implications for treatment adherence. 
The strengths of this study are sample size and homoge-
neity (males with ﬁ  rst-episode schizophrenia, mostly drug-
naïve on admission). The ﬁ  ndings are limited by the fact 
that the study was open, performed under routine clinical 
conditions and 25% of the patients could not be reached or 
declined to attend the reassessment. 
Conclusion 
The ﬁ  rst episode of schizophrenia is characterized by pro-
nounced treatment response which may not be the case in a 
portion of patients during the further course of the disease 
from the ﬁ  rst psychotic break-down. After the acute treat-
ment and at 1-year follow-up the most frequent symptoms 
were negative and non-speciﬁ  c general symptoms. At the 
1-year follow-up the impairment of insight and judgment 
is one of the most frequent symptoms in both remitters and 
non-remitters. This conﬁ  rms the suggestion that the period 
after the ﬁ  rst psychotic manifestation constitutes a critical 
period. Longitudinal follow-up of ﬁ  rst-episode patients is of 
great interest in addressing this question. 
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